Molecular Partners reports clinical progress

In English
Auf Deutsch
Bio-Technopark Schlieren-ZürichOffizielles

CURRENT TRENDS IN EARLY PHASE CLINICAL RESEARCH

Please join us for an engaging discussion and some food and drinks!
 
Registration is easy and can be found here; https://www.eventbrite.com/e/current-trends-in-early-phase-clinical-research-tickets-1728190467209?aff=oddtdtcreator

James Sawyers
Business Development Manager
Clinical Development Phase I-IV, Regulatory, Pharmacovigilance & Market Access
T: +44 7342708404
E: james.sawyers@fortrea.com | fortrea.com
 

Bio-Technopark Schlieren-ZürichEvents

InSphero, ETH, and Children’s Hospital develop new microfluidics platform

In English
Auf Deutsch
Bio-Technopark Schlieren-ZürichOffizielles

CDR-Life presents initial study results

In Englisch
Auf Deutsch
Bio-Technopark Schlieren-ZürichOffizielles

Optimizing Bioprocessing: Precision Monitoring and Advanced Manufacturing

Amphacademy – Advancing Knowledge in Bioprocessing
Amphacademy Bioprocessing  is an onsite symposium to connect experts, innovators, and decision-makers around key topics in cell analysis and biotechnology. Amphacademy Bioprocessing creates a forum where science and industry meet to exchange knowledge and offers a platform for networking and interdisciplinary exchange.

The upcoming symposium is entitled  Optimizing Bioprocessing: Precision Monitoring and Advanced Manufacturing. Participants will learn about recent advancements in bioprocess development, progress in biomanufacturing technologies, and improvements in precision cell culture monitoring. Alongside expert talks and real-world case studies, the event will also introduce a breakthrough at-line cell analysis device designed for microbial fermentation.

More info and registration
Bio-Technopark Schlieren-ZürichEvents

InSphero announces winners of HUMAIN Award 2025

In English
Auf Deutsch
Bio-Technopark Schlieren-ZürichOffizielles

ImmunOs Therapeutics Reports Promising Clinical Activity

In English
Auf Deutsch
Bio-Technopark Schlieren-ZürichOffizielles

Kuros Biosciences reports 77% year-over-year increase

In English
Auf Deutsch
Bio-Technopark Schlieren-ZürichOffizielles

Neurimmune begins phase 2 trial treatment

In English
Auf Deutsch
Bio-Technopark Schlieren-ZürichOffizielles

Kuros Biosciences Inaugurates New US Site

In English
Auf Deutsch
Bio-Technopark Schlieren-ZürichOffizielles